Skip to content

Clinical trials

Observational Gastrointestinal Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Gastrointestinal Diseases Phase: Observational Country / region: United States Clear all

58 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20052
20061
20071
20082
20091
20101
20114
20122
20134
20145
20151
20163
20176
20181
20196
20213
20224
20234
20242
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed33
Enrolling by invitation7
Recruiting7
Unknown status5
Active, not recruiting3
Terminated2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Exact Sciences Corporation6
Massachusetts General Hospital3
Methodist Health System3
AbbVie2
Boston Children's Hospital2
Children's Mercy Hospital Kansas City2
G-Tech Corporation2
Johns Hopkins Bloomberg School of Public Health2
Mayo Clinic2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Gastrointestinal Diseases58
Digestive System Diseases20
Neoplasms12
Colorectal Neoplasms10
Gastrointestinal Neoplasms10
Intestinal Diseases9
Colonic Diseases8
Digestive System Neoplasms8
Intestinal Neoplasms8
Neoplasms by Site8

Trials

Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.